BioCentury
ARTICLE | Clinical News

ATL-1102: Phase IIa start

January 23, 2006 8:00 AM UTC

The companies will restart this quarter a double-blind, placebo-controlled, German Phase IIa trial in 80 relapsing-remitting MS patients with 400 mg weekly subcutaneous ATL1102. The trial was halted ...